AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01169025 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Subjects receive 1 mcg/kg IV fentanyl over 5 minutes. After first dose administration, subjects are evaluated every 10 minutes. Residual or recurring pain is treated as needed with adjunctive open-label bolus dosing of IV fentanyl (1 mcg/kg) followed by repeat boluses as needed every 10 minutes during the flight. For this open-label portion of the flight, flight nurses will query participants regarding their desire for additional pain medication every 10 minutes unless an earlier, spontaneous request is made by the participant or the provider determines that more is needed. Vital signs are measured continuously throughout the protocol. Blood pressure is measured at 5 minute intervals.
Study NCT04731285 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Pressure wire fractional flow reserve
Description: Pressure wire is inserted into coronary arteries. The ratio of the average distal pressure and average aorta pressure is FFR.
Study NCT04731285 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CFD-based RuiXin-FFR
Description: CT-FFR was evaluated in a blinded fashion with a Coarse-to-Fine Subpixel algorithm for lumen contour
Study NCT02640638 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CenteringPregnancy
Description: 8-12 pregnant women whose due dates are in the same month will receive ten 2-hour group prenatal care sessions according to the standard curriculum provided by the Centering Healthcare Institute.
Study NCT02994563 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thrombectomy Device
Description: The Amnis Thrombectomy Device is intended to restore blood flow by removing thrombus from intracranial vessels in patients experiencing ischemic stroke
Study NCT02843906 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lombar Punction
Description: cerebrospinal fluid testing at screening and M36
Study NCT02843906 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging (MRI)
Description: MRI done at screening and M36
Study NCT02843906 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Positron-Emission Tomography (TEP) /(FDG)
Description: TEP/FDG done at screening and M36
Study NCT02843906 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychiatric tests
Study NCT02843906 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuropsychological Tests
Description: done at screening, M12, M24 and M36
Study NCT02843906 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: Apolipoprotein (ApoE) detection
Description: ApoE detection done at screening
Study NCT03146611 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: nCD64
Description: neutrophil CD64
Study NCT03146611 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Neutrophil/Lymphocyte Ratio
Description: Neutrophil/ lymphocyte ratio
Study NCT04234620 — intervention group
Intervention type: DRUG
Intervention: Toripalimab injection
Description: 240 mg/6 mL/vial. The recommended dose of Toripalima is 3 mg/kg, intravenous infusion every 2 weeks until disease progression or intolerable toxicity.
Study NCT03847844 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical cord derived mesenchymal stem cell
Description: Umbilical cord derived mesenchymal stem cell
Study NCT03847844 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study NCT04582786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine
Description: Repeated bolus according to pain score
Study NCT04582786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Morphine HCl
Description: Infusion of morphine HCl solution for intravenous administration
Study NCT04582786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STR-324
Description: Infusion of solution for intravenous administration
Study NCT04070365 — intervention group
Intervention type: DEVICE
Intervention: FLEX Vessel Prep System followed by angioplasty
Description: Eligible Arteriovenous Fistula (AVF)/Arteriovenous Graft (AVG) will be treated with the FLEX Vessel Prep system followed by angioplasty.
Study NCT04154046 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tenotomy(cutting) of flexor tendons is performed with needle
Description: Patient is placed in seated posture with feet elevated. The toe(s) with hammer, mallet or claw toe deformity is anesthetized by a digital toe block with 1-5 ml of 1% lidocaine administered for each toe. The toe digital block is administered through a plantar approach, at the web level of the deformed toe(s), with a 0,6 mm diameter and 30mm long needle.~After anesthetizing the toe(s) the plantar aspect of the toe at web level is disinfected with an alcohol based disinfectant twice.~Both the long and short flexors are then severed with a 1.2mm diameter and 40mm long needle through a plantar approach, immediately proximal to the web level of the toe.~After the procedure a dry gauze bandage is applied and the patients treated foot/feet is/are elevated for 20 minutes to achieve haemostasis, and the bandage is checked for bleeding before discharge.
Study NCT02428777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol
Description: Women will receive oral tramadol 100 mg 1 hour before the procedure.
Study NCT02428777 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: Women will receive oral diclofenac 100 mg 1 hour before the procedure
Study NCT02428777 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Women will receive an oral placebo 1 hour before the procedure
Study NCT03360123 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam Hydrochloride 2Mg/mL Syrup
Description: Midazolam HCl Syrup 0.5mg/kg (Max: 15mg) taken 10-15 minutes prior to dental treatment.
Study NCT03360123 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triazolam 0.125 MG
Description: Triazolam: 0.125mg tablet taken 30 minutes prior to dental treatment.
Study NCT01673828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allopregnanolone injection
Description: Allopregnanolone intravenous solution in 0.9% sodium chloride injection with 6% sulfobutyl ether β-cyclodextrin sodium
Study NCT01673828 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo injection
Description: Placebo intravenous solution, 0.9% sodium chloride injection with 6% sulfobutyl ether β-cyclodextrin sodium
Study NCT04364828 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: Whole Genome Analysis
Description: Whole Genome Analysis with whole transcriptome analysis and deoxyribonucleic acid (DNA) methylation analysis using Methylation beadchip (EPIC) arrays
Study NCT04364828 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: T-cell receptor (TCR) repertoire
Description: Longitudinal analysis of TCR repertoire of Cluster of Differentiation 4+ (CD4+) and CD8+ T cells from blood samples (Peripheral Blood Mononuclear Cells, PBMCs) from clinically characterized patients
Study NCT04364828 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: SARS-CoV-2 viral composition
Description: Determined by Next Generation sequencing
Study NCT02784795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3039478
Description: Administered orally
Study NCT02784795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Taladegib
Description: Administered orally
Study NCT02784795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally
Study NCT02784795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Administered IV
Study NCT02784795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Administered IV
Study NCT02784795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Administered IV
Study NCT02784795 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3023414
Description: Administered orally
Study NCT03952013 — intervention group
Intervention type: OTHER
Intervention: To explore health literacy levels in patients hospitalized for acute neuro-cardiovascular diseases i.e. stroke, myocardial infarction, or heart failure
Description: All patients included and followed within one of the three cohorts studies: LOOP-HF, HIBISCUS-STEMI and HIBISCUS-STROKE who accepted to participate in the study, will be contacted by phone (attempted calls are set to 3 to reach the patient), mail or during a consultation, to answer to a health literacy questionnaire. The patient will participate in the study only once. The estimated duration is therefore estimated at 1 day for each patient and two month for the study. Thanks to the many following periods within the cohorts (6 months, 1 year and 18 month), we will measure health literacy at different times of the care.
Study NCT02103309 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Nelfilcon A contact lenses
Study NCT00933751 — intervention group
Intervention type: DEVICE
Intervention: Central vein catheterization
Description: Blood samplings from IVC catheter
Study NCT00282256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus modified release (MR)
Description: Oral
Study NCT02103309 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Etafilcon A contact lenses
Study NCT00282256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Oral
Study NCT05031728 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Description: Cognitive processing therapy (CPT) (Resick et al., 2016) which is a specific type of cognitive behavioral therapy that has been effective in reducing symptoms of Post-Traumatic Stress Disorder (PTSD) that may have developed after experiencing a variety of traumatic events including child abuse, emotional abuse, combat, rape war, and natural disasters. CPT helps patients learn how to challenge and modify unhelpful beliefs related to the trauma and emotional pain. In so doing, the client creates a new understanding and conceptualization of the traumatic event so that it reduces its ongoing negative effects on current life.
Study NCT06203314 — intervention group
Intervention type: OTHER
Intervention: Diagnostic test: EBV antibody tests
Description: Participants underwent several EBV antibody tests, including VCA-IgA, EBNA1-IgA, etc.
Study NCT02728037 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnesium-Based Injection Formulation
Description: Each study kit will include 4 10cc syringes containing 7ml of 1% lidocaine, and 3 numbered glass vials. For those in the magnesium-based injection formulation arm the glass vials will be prepared as follows; 1) 10ml of 50% magnesium sulfate, 2) 20ml of 8.4% bicarbonate, and 3) 20ml of 50% dextrose.~At the visit a study investigator will mix 2cc of vial 1, 5cc of vial 2 and 5cc of vial 3, for a total of 12cc of additive mixture. 3cc of this additive mixture will be then drawn in to each of the 4 pre-packaged lidocaine syringes, for a total of 10cc of final mixture per syringe. The concentration of components in the final mixture is 0.7% lidocaine, 0.8% sodium bicarbonate, 6.0% dextrose, and 2.5% magnesium sulfate.
Study NCT02654548 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Sebutape
Description: Women who consent to the study will have a sebutape attached to their and their babies foreheads to measure the levels of androgens.
Study NCT02654548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sebutape
Description: Women who consent to the study will have a sebutape attached to their and their babies foreheads to measure the levels of androgens.
Study NCT03026699 — intervention group
Intervention type: BEHAVIORAL
Intervention: eSNAP
Description: Participants in the intervention group will then be given a tablet loaded with the eSNAP application and asked to create a visualization of their social networks. Upon completion, participants will be asked to review their ecomaps and complete the user experience questionnaire.
Study NCT03026699 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaires
Description: Participants will complete demographics and baseline (T1; baseline) questionnaires. For all participants Time 2 (T2; 3 week) and Time 3 (T3; 6 week) questionnaires will be completed either by phone, mail, or email (depending on participant preference) to assess longer-term effects of eSNAP on outcomes versus controls.
Study NCT02728037 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine-Only Injection Formulation
Description: Each study kit will include 4 10cc syringes containing 7ml of 1% lidocaine, and 3 numbered glass vials. For those in the lidocaine-based injection formulation arm the glass vials will be prepared as follows; 1) 10ml of 0.9% sodium chloride, 2) 20ml of 0.9% sodium chloride, and 3) 20ml of 0.9% sodium chloride.~At the visit a study investigator will mix 2cc of vial 1, 5cc of vial 2 and 5cc of vial 3, for a total of 12cc of additive mixture. 3cc of this additive mixture will be then drawn in to each of the 4 pre-packaged lidocaine syringes, for a total of 10cc of final mixture per syringe. The concentration of components in the final mixture is 0.7% lidocaine.
Study NCT02728037 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine
Study NCT01253291 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2127399
Description: Administered subcutaneously every 4 weeks for 48 weeks
Study NCT00950586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK1043702
Description: Oral dose in liquid or tablet formulation
Study NCT00950586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextromethorphan
Description: 30mg Oral dose
Study NCT00950586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: To match GSK1034702
Study NCT02907151 — intervention group
Intervention type: OTHER
Intervention: Survey
Description: Complete a survey prior to the consultation and a questionnaire after
Study NCT00880620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study NCT00880620 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00880620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPX066 95 mg LD
Description: IPX066 capsule containing 95 mg LD/23.75 mg CD
Study NCT00880620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPX066 145 mg LD
Description: IPX066 capsule containing 145 mg LD/36.25 mg CD
Study NCT02728037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaine
Study NCT00880620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPX066 195 mg LD
Description: IPX066 capsule containing 195 mg LD/48.75 mg CD
Study NCT00880620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPX066 245 mg LD
Description: IPX066 capsule containing 245 mg LD/61.25 mg CD
Study NCT02108249 — intervention group
Intervention type: DEVICE
Intervention: Annex™ Adjacent Level System
Study NCT00951366 — intervention group
Intervention type: OTHER
Intervention: Patient Registry
Description: The CHILD Clinic Patient Registry is an observational study designed to identify epidemiologic and genetic factors associated with chronic lung disease in former preterm infants or those with lung disease in the neonatal period.
Study NCT05899439 — intervention group
Intervention type: OTHER
Intervention: blood draw
Description: a peripheral blood draw
Study NCT06443372 — intervention group
Intervention type: OTHER
Intervention: Clinical periodontal measurements, GCF sampling
Description: Clinical periodontal measuements included PD, CAL, BOP (+/-), GI, and PI. Clinical recordings were performed at six points (mesiobuccal, buccal, distobuccal, mesiopalatal, palatal, and distopalatal) of all teeth, except the 3rd molars.~GCF samples were obtained 1 day following the clinical measurements. GCF was sampled with paper strips from two deepest pockets in periodontitis group; the most inflamed sites with clinical signs of redness or edema in gingivitis group; and the sites without visible inflammation in periodontally healthy group. GCF and saliva samples were stored at -80 °C until further analysis.
Study NCT03416140 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic Exercise
Description: 30 minutes per day of therapeutic exercise
Study NCT03549221 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.6 mg 1:1000 epinephrine (0.6 ml)
Description: In group 1, the multimodal anesthetic cocktail consisted of 100 mg Levobupivacaine (0.5%, 20 mL) 30 mg ketorolac (1 ml) and 0.6 mg 1:1000 epinephrine (0.6 ml). In group 2, the multimodal anesthetic cocktail consisted of 100 mg Levobupivacaine (0.5%, 20 mL) and 30 mg ketorolac (1 ml). Both groups were mixed with a 0.9% normal saline solution to a total volume of 100 ml.
Study NCT02210728 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylphenidate or amphetamine product
Description: Medication is titrated over a 4-week period with stepwise increments each week. Patients and significant others complete ADHD symptom scales at baseline and before each medication visit. Patients also complete side effects scales at baseline and before each medication visit. The gradual increase will continue until there is no further improvement in symptoms and in the Clinical Global Improvement Scale or side effects are such that further increases are not indicated. Once the optimal dose is reached, the subjects remain on this dose for the remainder of the study.
Study NCT02728037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: magnesium sulfate, bicarbonate, dextrose.
Study NCT03759821 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition, mothers
Description: Nutrition-related social and behavior change (SBC) messages and activities for mothers focused on infant and young child feeding (IYCF), dietary diversity, water, sanitation, and hygiene (WASH), food access (use of income and home-grown foods), psychosocial well-being, gender equity, intra-household resource allocation, partner communication and household decision-making
Study NCT03759821 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition, mothers and fathers
Description: Nutrition-related social and behavior change (SBC) messages and activities for mothers and fathers focused on infant and young child feeding (IYCF), dietary diversity, water, sanitation, and hygiene (WASH), food access (use of income and home-grown foods), psychosocial well-being, gender equity, intra-household resource allocation, partner communication and household decision-making
Study NCT03759821 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition+parenting, mothers
Description: Nutrition- and parenting-related social and behavior change (SBC) messages and activities for mothers focused on infant and young child feeding (IYCF), dietary diversity, responsive caregiving and child stimulation (play and communication), water, sanitation, and hygiene (WASH), food access (use of income and home-grown foods), psychosocial well-being, gender equity, intra-household resource allocation, partner communication and household decision-making
Study NCT03759821 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition+parenting, mothers and fathers
Description: Nutrition- and parenting-related social and behavior change (SBC) messages and activities for mothers and fathers focused on infant and young child feeding (IYCF), dietary diversity, responsive caregiving and child stimulation (play and communication), water, sanitation, and hygiene (WASH), food access (use of income and home-grown foods), psychosocial well-being, gender equity, intra-household resource allocation, partner communication and household decision-making
Study NCT03576391 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control condition
Description: 45 minute rest while seated. Watching an animated movie, sleeping was not allowed.
Study NCT03576391 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rapid Arm Movements
Description: 2 blocks of 80 trials of RAM in either a forward (n = 40) or backward (n = 40) shoulder flexion direction and back to neutral as fast as possible, with maintaining extension in the elbow. Visual cues (arrows) indicated the movement direction.
Study NCT02210728 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive behavioral therapy
Description: 12 sessions of group cognitive behavioral therapy. Participants also receive individual coaching 3 times a week (twice over telephone and once in person). Coaching sessions are 15 minutes each in duration and are aimed at implementation, practice, and generalization of skills acquired in therapy.
Study NCT02210728 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive behavioral therapy
Description: 12 sessions of group cognitive behavioral therapy. Participants also receive individual coaching 3 times a week (twice over telephone and once in person). Coaching sessions are 15 minutes each in duration and are aimed at implementation, practice, and generalization of skills acquired in therapy.
Study NCT03641937 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: INVSENSOR00011
Description: INVSENSOR00011 - investigational sensor that will be placed on the subject's chest and/or back for the duration of the study.
Study NCT03852134 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MOCC Group
Description: After 30 seconds of DCC, the cord will be clamped and cut 5 cm from the introitus in vaginal delivery or abdominal incision in the case of cesarean section before passing the infant with the long umbilical cord segment to the pediatric provider who will milk the cord one time towards the baby during resuscitation.